ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Courtney D DiNardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.